Literature DB >> 28337525

Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a.

Jillian R Hufgard1, Michael T Williams1, Matthew R Skelton1, Olivera Grubisha2, Filipa M Ferreira2, Helen Sanger2, Mary E Wright3, Tracy M Reed-Kessler3, Kurt Rasmussen4, Ronald S Duman5, Charles V Vorhees6.   

Abstract

RATIONALE: Major depressive disorder is a leading cause of suicide and disability. Despite this, current antidepressants provide insufficient efficacy in more than 60% of patients. Most current antidepressants are presynaptic reuptake inhibitors; postsynaptic signal regulation has not received as much attention as potential treatment targets.
OBJECTIVES: We examined the effects of disruption of the postsynaptic cyclic nucleotide hydrolyzing enzyme, phosphodiesterase (PDE) 1b, on depressive-like behavior and the effects on PDE1B protein in wild-type (WT) mice following stress.
METHODS: Littermate knockout (KO) and WT mice were tested in locomotor activity, tail suspension (TST), and forced swim tests (FST). FST was also used to compare the effects of two antidepressants, fluoxetine and bupropion, in KO versus WT mice. Messenger RNA (mRNA) expression changes were also determined. WT mice underwent acute or chronic stress and markers of stress and PDE1B expression were examined.
RESULTS: Pde1b KO mice exhibited decreased TST and FST immobility. When treated with antidepressants, both WT and KO mice showed decreased FST immobility and the effect was additive in KO mice. Mice lacking Pde1b had increased striatal Pde10a mRNA expression. In WT mice, acute and chronic stress upregulated PDE1B expression while PDE10A expression was downregulated after chronic but not acute stress.
CONCLUSIONS: PDE1B is a potential therapeutic target for depression treatment because of the antidepressant-like phenotype seen in Pde1b KO mice.

Entities:  

Keywords:  Forced swim test; PDE1B; Pde brain gene expression; Pde1b knockout mice; Phosphodiesterase; Stress resistance

Mesh:

Substances:

Year:  2017        PMID: 28337525     DOI: 10.1007/s00213-017-4587-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  57 in total

1.  Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.

Authors:  Peng Li; Hailin Zheng; Jun Zhao; Lei Zhang; Wei Yao; Hongwen Zhu; J David Beard; Koh Ida; Weston Lane; Gyorgy Snell; Satoshi Sogabe; Charles J Heyser; Gretchen L Snyder; Joseph P Hendrick; Kimberly E Vanover; Robert E Davis; Lawrence P Wennogle
Journal:  J Med Chem       Date:  2016-02-02       Impact factor: 7.446

Review 2.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 3.  Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls.

Authors:  Rolf T Hansen; Han-Ting Zhang
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  Role of phosphodiesterases in neurological and psychiatric disease.

Authors:  Andrea L O Hebb; Harold A Robertson
Journal:  Curr Opin Pharmacol       Date:  2006-11-20       Impact factor: 5.547

5.  Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation.

Authors:  Claudio C Filgueiras; Thomas E Krahe; Alexandre E Medina
Journal:  Neurosci Lett       Date:  2010-02-26       Impact factor: 3.046

6.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

7.  Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Baldev Gautam; Shvetank Bhatt; Dilip Pandey
Journal:  Eur J Pharmacol       Date:  2012-06-12       Impact factor: 4.432

8.  Female mice heterozygous for creatine transporter deficiency show moderate cognitive deficits.

Authors:  Emily R Hautman; Amanda N Kokenge; Kenea C Udobi; Michael T Williams; Charles V Vorhees; Matthew R Skelton
Journal:  J Inherit Metab Dis       Date:  2013-05-29       Impact factor: 4.982

9.  Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor.

Authors:  Ashish Dhir; S K Kulkarni
Journal:  Fundam Clin Pharmacol       Date:  2008-08       Impact factor: 2.748

10.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Authors:  J A Siuciak; S A McCarthy; D S Chapin; T M Reed; C V Vorhees; D R Repaske
Journal:  Neuropharmacology       Date:  2007-04-29       Impact factor: 5.250

View more
  8 in total

Review 1.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

2.  Phosphodiesterase-1b deletion confers depression-like behavioral resistance separate from stress-related effects in mice.

Authors:  J R Hufgard; M T Williams; C V Vorhees
Journal:  Genes Brain Behav       Date:  2017-06-07       Impact factor: 3.449

3.  A comparison of the sexually dimorphic dexamethasone transcriptome in mouse cerebral cortical and hypothalamic embryonic neural stem cells.

Authors:  Krystle A Frahm; Jacob K Waldman; Soumya Luthra; Anthony C Rudine; A Paula Monaghan-Nichols; Uma R Chandran; Donald B DeFranco
Journal:  Mol Cell Endocrinol       Date:  2017-05-26       Impact factor: 4.102

4.  An insight into reactivity and bioactivity properties of quorum sensing peptides against PDE10A: a computational peptidology approach.

Authors:  Bhargav Shreevatsa; Chandan Dharmashekara; Anisha S Jain; Raghavendra Amachawadi; Asad Syed; Chandan Shivamallu; Shiva Prasad Kollur; Juan Frau; Norma Flores-Holguín; Daniel Glossman-Mitnik; Raghu Ram Achar
Journal:  J Mol Model       Date:  2022-07-05       Impact factor: 2.172

5.  Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns.

Authors:  Carla Carratalá-Ros; Régulo Olivares-García; Andrea Martínez-Verdú; Edgar Arias-Sandoval; John D Salamone; Mercè Correa
Journal:  Psychopharmacology (Berl)       Date:  2021-09-09       Impact factor: 4.415

6.  Multiple rare inherited variants in a four generation schizophrenia family offer leads for complex mode of disease inheritance.

Authors:  Jibin John; Upasana Bhattacharyya; Navneesh Yadav; Prachi Kukshal; Triptish Bhatia; V L Nimgaonkar; Smita N Deshpande; B K Thelma
Journal:  Schizophr Res       Date:  2019-12-05       Impact factor: 4.939

7.  Additive antidepressant-like effects of fasting with β-estradiol in mice.

Authors:  Pu Wang; Bingjin Li; Jie Fan; Kun Zhang; Wei Yang; Bingzhong Ren; Ranji Cui
Journal:  J Cell Mol Med       Date:  2019-06-18       Impact factor: 5.310

Review 8.  Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders.

Authors:  Sébastien Delhaye; Barbara Bardoni
Journal:  Mol Psychiatry       Date:  2021-01-07       Impact factor: 15.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.